Batiraxcept - Aravive
Alternative Names: 3D-229; 3D-299; Aravive-S6; AVB 500; AVB S6 500; Axl fc fusion protein AVB-S6-500; Ruga-S6; S6-500cLatest Information Update: 18 Jul 2024
At a glance
- Originator Stanford University
- Developer 3D Medicines; Aravive; Aravive Biologics; European Network of Gynaecological Oncological Trial Groups; Gynecologic Oncology Group
- Class Antifibrotics; Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Proteins; Recombinant fusion proteins
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Cholangiocarcinoma; Fallopian tube cancer; IgA nephropathy; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Renal fibrosis; Solid tumours; Unspecified; Urogenital cancer; Viral infections
Most Recent Events
- 31 May 2024 Efficacy data from a phase III AXLerate-OC trial in Ovarian cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 Jan 2024 Discontinued - Phase-III for Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in Czech Republic (IV)
- 31 Jan 2024 Discontinued - Phase-III for Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in Italy (IV)